In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Alphatec Holdings (ATEC), with a price target of $4. The company’s shares closed on Friday at $1.95, equals to its 52-week low of $1.95.
Ramakanth observed:
“We are maintaining our Buy rating of ATEC and our 12-month price target of $4.00 per diluted share. We derive our price target based on: 1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2025 sales of $244M; and 2) a discounted cash flow analysis using the projected free cash flow to the firm through 2025 and assuming a 10% discount rate and 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $3.87 per share, which we round to $4.00.”
According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.8% and a 30.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.
Alphatec Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $4.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.21 and a one-year low of $1.95. Currently, Alphatec Holdings has an average volume of 86.49K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alphatec Holdings, Inc. designs, develops, and markets spinal fusion technology products and solutions for the treatment of spinal disorders. The company products portfolio include biologics, cervical, interbody, minimally invasive surgery, and thoracolumbar. It operates through the United States and International geographical segments.
